PMID- 38137495
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231225
IS  - 2227-9059 (Print)
IS  - 2227-9059 (Electronic)
IS  - 2227-9059 (Linking)
VI  - 11
IP  - 12
DP  - 2023 Dec 11
TI  - Autologous Faecal Microbiota Transplantation to Improve Outcomes of 
      Haematopoietic Stem Cell Transplantation: Results of a Single-Centre Feasibility 
      Study.
LID - 10.3390/biomedicines11123274 [doi]
LID - 3274
AB  - Haematopoietic stem cell transplantation (HSCT) is a curative approach for blood 
      cancers, yet its efficacy is undermined by a range of acute and chronic 
      complications. In light of mounting evidence to suggest that these complications 
      are linked to a dysbiotic gut microbiome, we aimed to evaluate the feasibility of 
      faecal microbiota transplantation (FMT) delivered during the acute phase after 
      HSCT. Of note, this trial opted for FMT prepared using the individual's own stool 
      (autologous FMT) to mitigate the risks of disease transmission from a donor 
      stool. Adults (>18 years) with multiple myeloma were recruited from a single 
      centre. The stool was collected prior to starting first line therapy. Patients 
      who progressed to HSCT were offered FMT via 3 x retention enemas before day +5 
      (HSCT = day 0). The feasibility was determined by the recruitment rate, number 
      and volume of enemas administered, and the retention time. Longitudinally 
      collected stool samples were also collected to explore the influence of auto-FMT 
      using 16S rRNA gene sequencing. n = 4 (2F:2M) participants received auto-FMT in 
      12 months. Participants received an average of 2.25 (1-3) enemas 43.67 (25-50) mL 
      total, retained for an average of 60.78 (10-145) min. No adverse events (AEs) 
      attributed to the FMT were identified. Although the minimum requirements were met 
      for the volume and retention of auto-FMT, the recruitment was significantly 
      impacted by the logistical challenges of the pretherapy stool collection. This 
      ultimately undermined the feasibility of this trial and suggests that third party 
      (donor) FMT should be prioritised.
FAU - Li, Anna
AU  - Li A
AUID- ORCID: 0000-0002-3135-5950
AD  - School of Biomedicine, The University of Adelaide, Adelaide, SA 5000, Australia.
AD  - Supportive Oncology Research Group, Precision Cancer Medicine, The South 
      Australian Health and Medical Research Institute, Adelaide, SA 5001, Australia.
FAU - Bowen, Joanne M
AU  - Bowen JM
AD  - School of Biomedicine, The University of Adelaide, Adelaide, SA 5000, Australia.
FAU - Ball, Imogen A
AU  - Ball IA
AD  - Department of Gastroenterology, Basil Hetzel Institute, The Queen Elizabeth 
      Hospital, Adelaide, SA 5011, Australia.
FAU - Wilson, Sophie
AU  - Wilson S
AD  - Department of Haematology, The Royal Adelaide Hospital, SA Health, Adelaide, SA 
      5000, Australia.
FAU - Yong, Angelina
AU  - Yong A
AD  - Department of Haematology, The Royal Adelaide Hospital, SA Health, Adelaide, SA 
      5000, Australia.
FAU - Yeung, David T
AU  - Yeung DT
AD  - Department of Haematology, The Royal Adelaide Hospital, SA Health, Adelaide, SA 
      5000, Australia.
FAU - Lee, Cindy H
AU  - Lee CH
AD  - Department of Haematology, The Royal Adelaide Hospital, SA Health, Adelaide, SA 
      5000, Australia.
FAU - Bryant, Robert V
AU  - Bryant RV
AD  - Department of Gastroenterology, Basil Hetzel Institute, The Queen Elizabeth 
      Hospital, Adelaide, SA 5011, Australia.
FAU - Costello, Samuel P
AU  - Costello SP
AD  - Department of Gastroenterology, Basil Hetzel Institute, The Queen Elizabeth 
      Hospital, Adelaide, SA 5011, Australia.
FAU - Ryan, Feargal J
AU  - Ryan FJ
AD  - College of Medicine and Public Health, Flinders University, Bedford Park, SA 
      5042, Australia.
AD  - Lynn Systems Immunology Group, Computational and Systems Biology Program, 
      Precision Cancer Medicine, The South Australian Health and Medical Research 
      Institute, Adelaide, SA 5001, Australia.
FAU - Wardill, Hannah R
AU  - Wardill HR
AUID- ORCID: 0000-0002-6613-3661
AD  - School of Biomedicine, The University of Adelaide, Adelaide, SA 5000, Australia.
AD  - Supportive Oncology Research Group, Precision Cancer Medicine, The South 
      Australian Health and Medical Research Institute, Adelaide, SA 5001, Australia.
LA  - eng
GR  - APP1140992/National Health and Medical Research Council/
GR  - 2021/81-QA25313/Hospital Research Foundation/
GR  - 9766/Royal Adelaide Hospital/
PT  - Journal Article
DEP - 20231211
PL  - Switzerland
TA  - Biomedicines
JT  - Biomedicines
JID - 101691304
PMC - PMC10741751
OTO - NOTNLM
OT  - HSCT
OT  - autologous faecal microbiota transplantation
OT  - autologous haematopoietic stem cell transplantation
OT  - bone marrow transplantation
OT  - faecal microbiota transplantation
OT  - gut microbiome
OT  - gut microbiota
OT  - haematopoietic stem cell transplantation
OT  - multiple myeloma
OT  - supportive care
OT  - supportive oncology
COIS- The authors declare no conflict of interest. The funders had no role in the 
      design of the study; in the collection, analyses, or interpretation of the data, 
      in the writing of the manuscript, or in the decision to publish the results.
EDAT- 2023/12/23 12:44
MHDA- 2023/12/23 12:45
PMCR- 2023/12/11
CRDT- 2023/12/23 01:10
PHST- 2023/11/07 00:00 [received]
PHST- 2023/12/01 00:00 [revised]
PHST- 2023/12/07 00:00 [accepted]
PHST- 2023/12/23 12:45 [medline]
PHST- 2023/12/23 12:44 [pubmed]
PHST- 2023/12/23 01:10 [entrez]
PHST- 2023/12/11 00:00 [pmc-release]
AID - biomedicines11123274 [pii]
AID - biomedicines-11-03274 [pii]
AID - 10.3390/biomedicines11123274 [doi]
PST - epublish
SO  - Biomedicines. 2023 Dec 11;11(12):3274. doi: 10.3390/biomedicines11123274.